Jeffrey C. Allen

Jeffrey C. Allen

Auto-generated profile, based on publicly available information

Jeffrey C. Allen

New York University, New York, NY

Research Focus & Metrics

Academic Career Length

53Years (1974-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 January 2002 in Nature
Verified
Journal Article
Closed access
PDF file
SPScott L. Pomeroy
Scott L. Pomeroy
PTPablo Tamayo
Pablo Tamayo
MGMichelle Gaasenbeek
Michelle Gaasenbeek
LSLisa M. Sturla
Lisa M. Sturla
MAMichael Angelo
Michael Angelo
TGTodd R. Golub
Todd R. Golub

1 May 2015 in Cancer Cell
Verified
Journal Article
Closed access
Kristian W. PajtlerKristian W. Pajtler
Kristian W. Pajtler
HWHendrik Witt
Hendrik Witt
MSMartin Sill
Martin Sill
DJDavid T.W. Jones
David T.W. Jones
VHVolker Hovestadt
Volker Hovestadt
Stefan PfisterStefan Pfister
Stefan Pfister

1 March 1999 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
PZPaul M. Zeltzer
Paul M. Zeltzer
JBJames M. Boyett
James M. Boyett
JFJonathan L. Finlay
Jonathan L. Finlay
AAA. Lel Albright
A. Lel Albright
LRLucy B. Rorke
Lucy B. Rorke
LHLi H
Li H
PURPOSE: From 1986 to 1992, “eight-drugs-in-one-day” (8-in-1) chemotherapy both before and after radiation therapy (XRT) (54 Gy tumor/36 Gy neuraxis) was compared with vincristine, lomustine (CCNU), and prednisone (VCP) after XRT in children with untreated, high-stage medulloblastoma (MB).PATIENTS AND METHODS: Two hundred three eligible patients with an institutional diagnosis of MB were stratified by local invasion and metastatic stage (Chang T/M) and randomized to therapy. Median time at risk from study entry was 7.0 years.RESULTS: Survival and progression-free survival (PFS) ± SE at 7 years were 55% ± 5% and 54% ± 5%, respectively. VCP was superior to 8-in-1 chemotherapy, with 5-year PFS rates of 63% ± 5% versus 45% ± 5%, respectively (P = .006). Upon central neuropathology review, 188 patients were confirmed as having MB and were the subjects for analyses of prognostic factors. Children aged 1.5 to younger than 3 years had inferior 5-year estimates of PFS, compared with children 3 years old or older (P = .0014; 32% ± 10% v 58% ± 4%, respectively). For MB patients 3 years of age or older, the prognostic effect of tumor spread (M0 v M1 v M2+) on PFS was powerful (P = .0006); 5-year PFS rates were 70% ± 5%, 57% ± 10%, and 40% ± 8%, respectively. PFS distributions at 5 years for patients with M0 tumors with less than 1.5 cm2of residual tumor, versus ≥ 1.5 cm2of residual tumor by scan, were significantly different (P = .023; 78% ± 6% v 54% ± 11%, respectively).CONCLUSION: VCP plus XRT is a superior adjuvant combination compared with 8-in-1 chemotherapy plus XRT. For patients with M0 tumors, residual tumor bulk (not extent of resection) is a predictor for PFS. Patients with M0 tumors, ≥ 3 years with ≤ 1.5 cm2residual tumor, had a 78% ± 6% 5-year PFS rate. Children younger than 3 years old who received a reduced XRT dosage had the lowest survival rate.

1 May 1997 in Journal of Neurosurgery
Verified
Journal Article
Closed access
RPRoger J. Packer
Roger J. Packer
JAJoanne Ater
Joanne Ater
JAJeffrey Allen
Jeffrey Allen
PPPeter Phillips
Peter Phillips
RGRussell Geyer
Russell Geyer
JBJames M. Boyett
James M. Boyett
✓ The optimum treatment of nonresectable low-grade gliomas of childhood remains undecided. There has been increased interest in the use of chemotherapy for young children, but little information concerning the long-term efficacy of such treatment. Seventy-eight children with a mean age of 3 years (range 3 months—16 years) who had newly diagnosed, progressive low-grade gliomas were treated with combined carboplatin and vincristine chemotherapy. The patients were followed for a median of 30 months from diagnosis, with 31 patients followed for more than 3 years. Fifty-eight children had diencephalic tumors, 12 had brainstem gliomas, and three had diffuse leptomeningeal gliomas. Forty-four (56%) of 78 patients showed an objective response to treatment. Progression-free survival rates were 75 ± 6% at 2 years and 68 ± 7% at 3 years. There was no statistical difference in progression-free survival rates between children with neurofibromatosis Type 1 and those without the disease (2-year, progression-free survival 79 ± 11% vs. 75 ± 6%, respectively). The histological subtype of the tumor, its location, and its maximum response to chemotherapy did not have an impact on the duration of disease control. The only significant prognostic factor was age: children 5 years old or younger at the time of treatment had a 3-year progression-free survival rate of 74 ± 7% compared with a rate of 39 ± 21% in older children (p < 0.01). Treatment with carboplatin and vincristine is effective, especially in younger children, in controlling newly diagnosed progressive low-grade gliomas.

1 July 1999 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
RPRoger J. Packer
Roger J. Packer
JGJoel Goldwein
Joel Goldwein
HNH. Stacy Nicholson
H. Stacy Nicholson
LVL. Gilbert Vezina
L. Gilbert Vezina
JAJeffrey C. Allen
Jeffrey C. Allen
JBJames M. Boyett
James M. Boyett
PURPOSE: Medulloblastoma is the most common malignant brain tumor of childhood. After treatment with surgery and radiation therapy, approximately 60% of children with medulloblastoma are alive and free of progressive disease 5 years after diagnosis, but many have significant neurocognitive sequelae. This study was undertaken to determine the feasibility and efficacy of treating children with nondisseminated medulloblastoma with reduced-dose craniospinal radiotherapy plus adjuvant chemotherapy. PATIENTS AND METHODS: Over a 3-year period, 65 children between 3 and 10 years of age with nondisseminated medulloblastoma were treated with postoperative, reduced-dose craniospinal radiation therapy (23.4 Gy) and 55.8 Gy of local radiation therapy. Adjuvant vincristine chemotherapy was administered during radiotherapy, and lomustine, vincristine, and cisplatin chemotherapy was administered during and after radiation. RESULTS: Progression-free survival was 86% ± 4% at 3 years and 79% ± 7% at 5 years. Sites of relapse for the14 patients who developed progressive disease included the local tumor site alone in two patients, local tumor site and disseminated disease in nine, and nonprimary sites in three. Brainstem involvement did not adversely affect outcome. Therapy was relatively well tolerated; however, the dose of cisplatin had to be modified in more than 50% of patients before the completion of treatment. One child died of pneumonitis and sepsis during treatment. CONCLUSION: These overall survival rates compare favorably to those obtained in studies using full-dose radiation therapy alone or radiation therapy plus chemotherapy. The results suggest that reduced-dose craniospinal radiation therapy and adjuvant chemotherapy during and after radiation is a feasible approach for children with nondisseminated medulloblastoma.

20 November 2017 in Journal of Clinical Oncology
Verified
Journal Article
Closed access
EKEdward S. Kim
Edward S. Kim
SBSuanna S. Bruinooge
Suanna S. Bruinooge
SRSamantha Roberts
Samantha Roberts
GIGwynn Ison
Gwynn Ison
NLNancy U. Lin
Nancy U. Lin
RSRichard L. Schilsky
Richard L. Schilsky
Purpose: The primary purposes of eligibility criteria are to protect the safety of trial participants and define the trial population. Excessive or overly restrictive eligibility criteria can slow trial accrual, jeopardize the generalizability of results, and limit understanding of the intervention’s benefit-risk profile. Methods: ASCO, Friends of Cancer Research, and the US Food and Drug Administration examined specific eligibility criteria (ie, brain metastases, minimum age, HIV infection, and organ dysfunction and prior and concurrent malignancies) to determine whether to modify definitions to extend trials to a broader population. Working groups developed consensus recommendations based on review of evidence, consideration of the patient population, and consultation with the research community. Results: Patients with treated or clinically stable brain metastases should be routinely included in trials and only excluded if there is compelling rationale. In initial dose-finding trials, pediatric-specific cohorts should be included based on strong scientific rationale for benefit. Later phase trials in diseases that span adult and pediatric populations should include patients older than age 12 years. HIV-infected patients who are healthy and have low risk of AIDS-related outcomes should be included absent specific rationale for exclusion. Renal function criteria should enable liberal creatinine clearance, unless the investigational agent involves renal excretion. Patients with prior or concurrent malignancies should be included, especially when the risk of the malignancy interfering with either safety or efficacy endpoints is very low. Conclusion: To maximize generalizability of results, trial enrollment criteria should strive for inclusiveness. Rationale for excluding patients should be clearly articulated and reflect expected toxicities associated with the therapy under investigation.